Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATL 101 - Telix Pharmaceuticals

Drug Profile

ATL 101 - Telix Pharmaceuticals

Alternative Names: 177Lu-J591; 90Y-J591; Anti-PSMA monoclonal antibody J591; Anti-PSMA-monoclonal-antibody-J-591-Lu-177; huJ 591; J 591; J-591-Lu-177; Lu-177-J591; Lu-177-MLN-591; Lutetium-177-labelled anti-PSMA monoclonal antibody J591; Lutetium-177-labelled-J-591; Lutetium-177labelled-MLN-591; MLN 591RL; MLN591; Monoclonal antibody J591; Monoclonal-antibody-J-591-Lu-177; muJ591; Radiolabelled J591; Radiolabelled MLN591

Latest Information Update: 25 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cornell University
  • Developer BZL Biologics; Telix Pharmaceuticals; Weill Cornell Medical College
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Prostate cancer; Solid tumours

Most Recent Events

  • 27 Feb 2023 Discontinued - Phase-I for Prostate cancer (Neoadjuvant therapy) in USA (IV)
  • 27 Feb 2023 Discontinued - Phase-I for Solid tumours (Metastatic disease) in USA (IV)
  • 27 Feb 2023 Discontinued - Phase-I/II for Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top